Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Twist Bioscience Corporation received an average rating of "Moderate Buy" from eleven analysts, with nine analysts issuing buy ratings and one each giving a sell and hold rating.
• The average 12-month price target for the company among analysts is $49.40, though recent price targets from several firms vary widely, with Goldman Sachs lowering theirs to $48.00.
• In its latest earnings report, Twist Bioscience reported an EPS of ($0.47), exceeding estimates, and had a revenue of $96.06 million for the quarter.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $49.40.

TWST has been the topic of a number of recent research reports. The Goldman Sachs Group lowered their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Evercore ISI set a $46.00 price objective on Twist Bioscience in a research note on Monday, August 4th. JPMorgan Chase & Co. lowered their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird lowered their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,678 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $60,005.28. Following the transaction, the chief executive officer owned 645,782 shares of the company's stock, valued at $23,093,164.32. This represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,250 shares of company stock worth $193,852. Corporate insiders own 3.01% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently modified their holdings of the business. Versant Capital Management Inc lifted its stake in shares of Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares during the last quarter. GAMMA Investing LLC lifted its stake in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares in the last quarter. Banque Transatlantique SA acquired a new position in Twist Bioscience during the 4th quarter worth about $43,000. GF Fund Management CO. LTD. acquired a new position in Twist Bioscience during the 4th quarter worth about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Twist Bioscience by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after acquiring an additional 302 shares in the last quarter.

Twist Bioscience Trading Up 8.0%

NASDAQ TWST traded up $2.12 on Thursday, reaching $28.59. 1,089,796 shares of the company were exchanged, compared to its average volume of 1,976,108. The business's fifty day moving average price is $33.54 and its 200 day moving average price is $36.29. The stock has a market capitalization of $1.73 billion, a P/E ratio of -19.72 and a beta of 2.36. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. Twist Bioscience has a fifty-two week low of $24.28 and a fifty-two week high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.